clinical trial · NCT07852962
Study to Assess Drug Levels, Immune Response, Safety and Tolerability of BMS-986446 in Healthy Chinese Participants.
Bristol-Myers Squibb·phase1·not yet recruiting·n = 10
Healthy VolunteersBMS-986446Placebo
brief summary
The purpose of this study is to assess the drug levels, immune response, safety and tolerability of BMS-986446 in healthy Chinese participants.
started
Feb 10, 2027
primary completion
Jul 18, 2027
completion
Jul 18, 2027
last updated
Oct 1, 2026
official title
A Phase 1, Double-blind, Randomized, Placebo-controlled, Single-dose Study to Evaluate the Pharmacokinetics, Immunogenicity, Safety, and Tolerability of BMS-986446 Following Intravenous Administration in Healthy Chinese Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol